References
S-179

Laparoscopic, Percutaneous, and MR-Guided Techniques for Myolysis

1. Food and Drug Administration. *Quantitative Assessment of the Prevalence of Unsuspected Uterine Sarcoma in Women Undergoing Treatment of Uterine Fibroids:* Summary and Key Findings. Silver Springs, MD: Food and Drug Administration; 2014.

2. Falk SJ, Barss VA. What's new in obstetrics and gynecology. UpToDate. Literature review current through: 2014.

3. Stewart, EA. Differentiating uterine leiomyomas (fibroids) from uterine sarcomas. UpToDate. Literature review current through: 2014.

4. Wright JD, Tergas AI, Burke WM, et al. Uterine pathology in women undergoing minimally invasive hysterectomy using morcellation. *JAMA.* 2014;69(11):653-654.

5. Gizzo S, Saccardi C, Patrelli TS, Noventa M, Fagherazzi B, et al. Magnetic resonance-guided focused ultrasound myomectomy: Safety, efficacy, subsequent fertility and quality-of-life improvements, a systematic review. *Reprod Sci*. 2014;21(4):465-476.

6. Hahn M, Brucker S, Kraemer D, Wallwiener M, Taran FA, et al. Radiofrequency volumetric thermal ablation of fibroids and laparoscopic myomectomy: Long-term follow-up from a randomized trial. *Geburtshilfe Frauenheilkd*. 2015;75(5):442-449.

7. Jacoby VL, Kohi MP, Poder L, Jacoby A, Lager J, et al. PROMISe trial: A pilot, randomized, placebo-controlled trial of magnetic resonance guided focused ultrasound for uterine fibroids. *Fertil Steril*. 2016;105(3):773-780.

8. Keltz J, Levie M, Chudnoff S. Pregnancy outcomes after direct uterine myoma thermal ablation: Review of the literature. *J Minim Invasive Gynecol.* 2017;24(4):538-545.

9. Sandberg EM, Tummers F, Cohen SL, van den Haak L, Dekkers OM, et al. Reintervention risk and quality of life outcomes after uterine-sparing interventions for fibroids: A systematic review and meta-analysis. *Fertil Steril.* 2018;109(4):698-707.

Laparoscopic Ultrasound-guided Radiofrequency Ablation

1. Brucker SY, Hahn M, Kraemer D, et al. Laparoscopic radiofrequency volumetric thermal ablation of fibroids versus laparoscopic myomectomy. *Int J Gynaecol Obstet*. 2014;125(3):261-265.

2. Kramer B, Hahn M, Taran FA, et al. Interim analysis of a randomized controlled trial comparing laparoscopic radiofrequency volumetric thermal ablation of uterine fibroids with laparoscopic myomectomy. *Int J Gynaecol Obstet*. 2016;133(2):206-211.

3. Havryliuk Y, Setton R, Carlow JJ, Shaktman BD. Symptomatic fibroid management: systematic review of the literature. *JSLS.* 2017;21(3): e2017.00041.

4. Hayes, Inc. Health Technology Breif. Laparoscopic Radiofrequency Volumetric Thermal Ablation (Acessa System; Halt Medical Inc.) for Treatment of Uterine Fibroids. November 3, 2017. Accessed February 5, 2018.

5. Gingold JA, Gueye NA, Falcone T. Minimally invasive approaches to myoma management. *Journal of Minimally Invasive Gynecology.* 2018;25(2):237-250.

6. Laughlin-Tommaso SK. Non-surgical management of myomas. *Journal of Minimally Invasive Gynecology.* 2018;25(2):229-236.

7. Havryliu Y, Setton R, Carlow JJ, Shaktman BD. Symptomatic fibroid management: Systematic review of the literature. *JSLS.* 2017;21(3):e2017.00041.

Transcatheter Uterine Artery Embolization

1. McLucas B, Voorhees WD 3rd, Chua KJ. Anti Müllerian hormone levels before and after uterine artery embolization: A preliminary report. *Minim Invasive Ther Allied Technol*. 2015;24:242-245.

2. de Bruijn AM, Ankum WM, Reekers JA, Birnie E, van der Kooij, et al. Uterine artery embolization vs hysterectomy in the treatment of symptomatic uterine fibroids: 10-year outcomes from the randomized EMMY trial. *Am J Obstet Gynecol*. 2016;215(6):741-745.

3. Yoon DJ, Jones M, Taani JA, Buhimschi C, Dowell JD. A systematic review of acquired uterine arteriovenous malformations: Pathophysiology, diagnosis, and transcatheter treatment. *AJP Rep*. 2016;6(1):e6-e14.

4. Committee on Practice Bulletins-Obstetrics. Practice Bulletin No. 183: Postpartum hemorrhage. *Obstet Gynecol.* 2017;130(4):e168-e186.

Endometrial Ablation

1. Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. *Cochrane Database Syst Rev.* 2016(1);1-97.

2. ACOG Practice Bulletin. Clinical Practice Guidelines for Obstetrician-Gynecologists. 2017(81). Reaffirmed 2018. Accessed July 25, 2018.

3. van den Brink MJ, Beelen P, Herman MC, Claassen NJJ, Bongers MY, et al. Women's preferences for levonorgestrel intrauterine system versus endometrial ablation for heavy menstrual bleeding, *Eur J Obstet Gynecol.* 2018. doi:10.1016/j.ejogrb.2018.06.020.

4. Panagiotopoulou N, Nethra S, Karavolos S, et al. Uterine-sparing minimally invasive interventions in women with uterine fibroids: A systematic review and indirect treatment comparison meta-analysis. *Acta Obstet Gynecol* Scand. 2014;3(9):858-867.

5. Dariushnia S., Nikolic B, Stokes L, et al. Quality improvement guidelines for uterine artery embolization for symptomatic leiomyomata. *J Vasc Interv Radiol*. 2014;25:1737–1747.

6. Hauk L; American College of Obstetricians and Gynecologists. ACOG releases guidelines on management of abnormal uterine bleeding associated with ovulatory dysfunction. *Am Fam Physician*. 2014;89(12):987-988.

7. Zhou J, He L, Liu P, et al. Outcomes in adenomyosis treated with uterine artery embolization are associated with lesion vascularity: A long-term follow-up study of 252 cases. *PLoS One.* 2016;11(11):e0165610.

8. Barnard EP, AbdElmagied AM, Vaughan LE, et al. Periprocedural outcomes comparing fibroid embolization and focused ultrasound: A randomized controlled trial and comprehensive cohort analysis. *Am J Obstet Gynecol.* 2017;216(5):500.e1-500.e11.

9. McCausland V, McCausland A, Barbis S. Partial endometrial ablation: A 10-20-year follow-up of impact on bleeding, pain, and quality of life. *J Gynecol Surg.* 2016; 32(4),230-235

10. Famuyide AO, Laughlin-Tommaso SK, Shazly SA, Long KH, Breitkopf DM, et al. Medical therapy versus radiofrequency endometrial ablation in the initial treatment of heavy menstrual bleeding (iTOM Trial): A clinical and economic analysis. *PLoS ONE.* 2017;12(11):e0188176.